TY - JOUR
T1 - Respiratory function, survival, and NIV prevalence over time in ALS - a PRECISION ALS study
AU - Sennfält, Stefan
AU - Al-Chalabi, Ammar
AU - Caravaca Puchades, Alejandro
AU - Chiò, Adriano
AU - Corcia, Philippe
AU - Galvin, Miriam
AU - Hardiman, Orla
AU - Heverin, Mark
AU - Hobin, Frederik
AU - Holmdahl, Oskar
AU - Lamaire, Nikita
AU - Mac Domhnaill, Éanna
AU - McDonough, Harry
AU - Manera, Umberto
AU - McDermott, Christopher J
AU - McFarlane, Robert
AU - Mouzouri, Mouhammed
AU - Ombelet, Fouke
AU - Opie-Martin, Sarah
AU - Povedano Panadés, Mónica
AU - Shaw, Pamela
AU - Terrafeta Pastor, Cristina
AU - Van Damme, Philipe
AU - van den Berg, Leonard
AU - van Eijk, Ruben P A
AU - Vasta, Rosario
AU - Veldink, Jan H
AU - Weemering, Daphne N
AU - Ingre, Caroline
N1 - Publisher Copyright:
© 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2025/5
Y1 - 2025/5
N2 - Introduction: Respiratory function typically deteriorates as ALS progresses and is associated with shorter survival. This study aims to describe respiratory function and the prevalence of noninvasive ventilation (NIV) along the disease trajectory using prospective data from the PRECISION ALS project. Methods: We included 3449 ALS patients from six European population-based cohorts. All had comparable assessments of vital capacity, percent predicted (VC%) (58.1% had multiple assessments) and 56% had assessments of the revised ALS Functional Rating Scale (ALSFRS-R). The data were analyzed in relation to survival, NIV, and genetic status (C9orf72, SOD1, FUS, and TARDBP). Results: In those with a survival time of 1–4 years from diagnosis, the median VC% declined from 91 to 97% at the first assessment to 47–50% at the last assessment 6 months before death. In those with longitudinal assessments, the median VC% declined an average of 24 percentage points per year. Over time, there was an increase in respiratory symptoms relative to general functional impairment, as measured by the ALSFRS-R, and VC% was strongly associated with shorter survival. The confirmed prevalence of NIV was approximately 3%, 15%, and 25% in patients with a VC% of >80, 50-80, and <50, respectively. Conclusion: There was a trend of worsening respiratory function over time and an increase in respiratory symptoms relative to general functional impairment. Survival was strongly associated with respiratory function. In those with impaired respiratory function, there was significant variation in the introduction of NIV.
AB - Introduction: Respiratory function typically deteriorates as ALS progresses and is associated with shorter survival. This study aims to describe respiratory function and the prevalence of noninvasive ventilation (NIV) along the disease trajectory using prospective data from the PRECISION ALS project. Methods: We included 3449 ALS patients from six European population-based cohorts. All had comparable assessments of vital capacity, percent predicted (VC%) (58.1% had multiple assessments) and 56% had assessments of the revised ALS Functional Rating Scale (ALSFRS-R). The data were analyzed in relation to survival, NIV, and genetic status (C9orf72, SOD1, FUS, and TARDBP). Results: In those with a survival time of 1–4 years from diagnosis, the median VC% declined from 91 to 97% at the first assessment to 47–50% at the last assessment 6 months before death. In those with longitudinal assessments, the median VC% declined an average of 24 percentage points per year. Over time, there was an increase in respiratory symptoms relative to general functional impairment, as measured by the ALSFRS-R, and VC% was strongly associated with shorter survival. The confirmed prevalence of NIV was approximately 3%, 15%, and 25% in patients with a VC% of >80, 50-80, and <50, respectively. Conclusion: There was a trend of worsening respiratory function over time and an increase in respiratory symptoms relative to general functional impairment. Survival was strongly associated with respiratory function. In those with impaired respiratory function, there was significant variation in the introduction of NIV.
KW - Adult
KW - Aged
KW - Amyotrophic Lateral Sclerosis/mortality
KW - C9orf72 Protein/genetics
KW - Cohort Studies
KW - Disease Progression
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Noninvasive Ventilation/statistics & numerical data
KW - Prevalence
KW - Prospective Studies
KW - Respiratory Insufficiency/therapy
U2 - 10.1080/21678421.2025.2454923
DO - 10.1080/21678421.2025.2454923
M3 - Article
C2 - 40326916
SN - 2167-8421
VL - 26
SP - 61
EP - 72
JO - Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
JF - Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
IS - sup1
ER -